Disrupting cancer through SurVaxM immunotherapy

At MimiVax, our mission is to disrupt cancer. We are dedicated to improving survival and sending hope to cancer patients

News and Events

The current study found that 51% of nGBM patients receiving SurVaxM had survived at least 2 years and 41% had survived 3 years, considerably higher rates than has been seen historically from standard care.

MimiVax is pleased to announce the published manuscript of the now completed Phase 2A study of SurVaxM, a cancer vaccine, in newly diagnosed glioblastoma (nGBM) in the Journal of Clinical Oncology, authored by researchers from several prominent US cancer centers. 
 
A follow-up Randomized, Blinded Placebo-Controlled Phase 2B Clinical trial of SurVaxM for nGBM (SURVIVE) [NCT05163080] is now recruiting at 10 cancer centers
across the USA.
 
Manuscript available at:
JCO.22.00996 

December 15, 2022

First center to treat newly diagnosed glioblastoma patients as part of late-stage trial with SurVaxM

“For years, we’ve struggled to move the needle as far as good treatment options for glioblastoma. Our hope is that SurVaxM will offer patients both longer survival and better quality of life,” says Dr. Abad, who is also an Assistant Professor of Oncology at Roswell Park. “To hopefully be on the precipice of meaningful progress against glioblastoma and to be able to possibly see my patients outside of the hospital — years after their diagnosis — would be incredible.”

February 4, 2022

Mimivax looks for game-changer in GBM as SurVaxM shows signal at interim look

In the ongoing study, survival trends strengthened as the data have matured. With the phase II in nGBM so far achieving a survival rate that exceeds the historical standard of care by 40 percent, the study already met its six-month PFS endpoint. 

May 21, 2018

MimiVax

Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates

PartnerING

MimiVax is improving outcomes and quality of life for those suffering from devastating diseases as well as strengthening the biomedical startup ecosystem of Buffalo, New York.

Pipeline

We’re exploring new ways of stimulating the immune system to fight cancer cells leveraging our proprietary survivin-targeting technology.

Clinical Trials

SurVaxM is presently being studied in glioblastoma (newly diagnosed and recurrent), multiple myeloma and neuroendocrine tumors (NET). 

OUR MISSION

To disrupt cancer with innovative immunotherapies

SurVaxM is currently being evaluated in: a Phase 2b clinical trial in adults with newly diagnosed glioblastoma; a Phase I clinical trial in combination with REVLIMID® (lenalidomide) for adults with multiple myeloma; and a Phase I clinical trial for metastatic neuroendocrine tumors (NET).

0
Clinical trials
0
Disease Indications
105
Patient Participants
1495
Doses Delivered

Disrupt cancer with the development of highly innovative immunotherapies

Partner with us

MimiVax is a privately held, clinical-stage biotechnology company that was formed in 2012 from Roswell Park Comprehensive Cancer Center. This was quickly followed by a prestigious award from the American Cancer Society, and support from the Roswell Park Alliance Foundation enabling clinical studies of SurVaxM for glioblastoma. If you are an investor interested in MimiVax, please reach out via the contact form below.

Contact us

To view a listing of investigational clinical trials open to patient enrollment that include SurVaxM, please visit clinicaltrials.gov.

For general inquiries: [email protected]

Help accelerate the pace of SurvaxM clinical trials

The Roswell Park Alliance Foundation is the charitable arm of Roswell Park Comprehensive Cancer Center, where SurVaxM research started. Donations to the Alliance Foundation helped make early phase SurVaxM clinical studies possible and will continue to accelerate the pace and scope of future SurVaxM clinical trials. Please follow this link to make a potentially life changing contribution to this critical effort.